多发性肌痛风湿是巨细胞动脉炎中更复发性疾病的危险因素:一项回顾性队列研究
Lien Moreel1, Albrecht Betrains1, Lennert Boeckxstaens2
1Department of General Internal Medicine, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium.
Seminars in arthritis and rheumatism
|July 5, 2024
概括
巨细胞动脉炎 (GCA) 患有多发性肌痛性风湿症 (PMR) 症状的患者经历了更持久的疾病,需要更长的葡萄糖皮质体 (GC) 治疗,并面临更高的复发风险. 这些患者还显示胸前大动脉动脉瘤的发病率降低.
科学领域:
- 类风湿病学 类风湿病学
- 内部医学 内部医学
- 血管炎研究 血管炎研究
背景情况:
- 巨细胞动脉炎 (GCA) 是一种大血管血管炎.
- 多发性肌痛风湿症 (PMR) 经常与GCA相关联.
- 了解与PMR相关的GCA表现和结果对于患者管理至关重要.
研究的目的:
- 为了比较GCA患者的临床表现和疾病结果,有或没有并发的PMR症状.
- 为了确定这些患者群体之间的治疗反应和长期并发症的差异.
主要方法:
- 在2000年至2020年期间诊断出398名GCA患者的回顾性分析.
- 患者被跟踪至少12个月.
- 在有或没有PMR症状的GCA患者之间,人口统计,临床和治疗数据的比较.
主要成果:
- 45%的GCA患者有PMR症状,症状持续时间较长.
- 与PMR相关的GCA患者需要更高的葡萄糖皮质激素 (GC) 剂量,GC停止的概率较低,治疗持续时间更长.
- 在患有PMR症状的患者中观察到复发风险增加 (64% vs 51%) 和复发的数量增加.
- 患有PMR症状的GCA患者的胸腔大动脉动脉瘤发生频率较低 (3%vs11%).
结论:
- 患有PMR症状的GCA患者表现出更反复的疾病过程.
- 这些患者需要更长时间和更高剂量的葡萄糖皮质醇治疗.
- 存在PMR症状与疾病复发风险增加有关.
更多相关视频
相关概念视频
Autoimmune Disorders
409
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
409
Genome-wide Association Studies-GWAS
13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.3K
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128


